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AbstrAct
Objective Rheumatoid arthritis (RA) is characterised 
by chronic inflammation leading to articular bone 
and cartilage damage. Despite recent progress in 
RA management, adverse effects, lack of efficacy 
and economic barriers to treatment access still limit 
therapeutic success. Therefore, safer and less expensive 
treatments that control inflammation and bone resorption 
are needed. We have previously shown that celastrol is 
a candidate for RA treatment. We have observed that it 
inhibits both interleukin (IL)-1β and tumor necrosis factor 
(TNF) in vitro, and that it has anti-inflammatory properties 
and ability to decrease synovial CD68+ macrophages in 
vivo. Herein our goal was to evaluate the effect of celastrol 
in local and systemic bone loss.
Methods Celastrol was administrated intraperitoneally 
at a dose of 1 µg/g/day to female Wistar adjuvant-
induced arthritic rats. Rats were sacrificed after 22 
days of disease progression, and blood, femurs, tibiae 
and paw samples were collected for bone remodelling 
markers quantification, 3-point bending test, micro-CT 
analysis, nanoindentation and Fourier transform infrared 
spectroscopy measurements, and immunohistochemical 
evaluation.
Results We have observed that celastrol preserved 
articular structures and decreased the number of 
osteoclasts and osteoblasts present in arthritic joints. 
Moreover, celastrol reduced tartrate-resistant acid 
phosphatase 5b, procollagen type 1 amino-terminal 
propeptide and C terminal crosslinked telopeptide of type 
II collagen serum levels. Importantly, celastrol prevented 
bone loss and bone microarchitecture degradation. 
Celastrol also preserved bone nanoproperties and mineral 
content. Additionally, animals treated with celastrol had 
less fragile bones, as depicted by an increase in maximum 
load and yield displacement.
Conclusions These results suggest that celastrol reduces 
both bone resorption and cartilage degradation, and 
preserves bone structural properties.
IntROduCtIOn
Rheumatoid arthritis (RA) is a chronic 
immune-mediated inflammatory disease with 
an estimated worldwide prevalence of 1%. 
RA is characterised by chronic oedema and 
inflammation of the synovial tissue that lines 
the joints. As disease progresses, cartilage 
and bone are damaged, leading to articular 
destruction.1 This periarticular and systemic 
bone loss is responsible for an increased risk 
of fracture in patients.2–5 Bone loss in RA 
results from an imbalance between the osteo-
blastic synthesis and osteoclastic degradation 
of bone, with bone resorption dominating 
over bone formation.6
We have previously reported increased levels 
of interleukin (IL)-1β in very recent onset 
arthritis and in the synovial fluid of patients 
with established RA.7 This may be explained 
by the activation of caspase-1, responsible for 
the processing of pro-IL-1β, which we have 
also observed to be increased since early 
RA.8 Through an in vitro drug screening 
using the THP-1 macrophage-like cell line, 
we have identified compounds that decrease 
the production of IL-1β and tumor necrosis 
factor (TNF), another central proinflamma-
tory cytokine of RA physiopathology. Among 
them, celastrol was identified as a promising 
therapeutic candidate for arthritis due to its 
ability to downregulate the production of 
IL-1β and TNF, by inhibiting both the activa-
tion of caspase-1 and nuclear factor kappa B 
(NF-kB).9 Celastrol is a pentacyclic-triterpene 
extracted from a plant used in traditional 
Chinese medicine, the Tripterygium wilfordii 
Hook F (TwHF). The anti-inflammatory 
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Animal models
Key messages
What is already known about this subject? 
 ► Celastrol has anti-inflammatory properties.
What does this study add?
 ► Celastrol reduces bone resorption and cartilage 
degradation.
 ► Celastrol preserves bone structure.
How might this impact on clinical practice?
 ► Based on these data on animal models Celastrol 
may serve as a useful therapeutic agent for 
rheumatoid arthritis.
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properties of celastrol have been mainly attributed to 
the regulation of cytokine and chemokine production 
and inflammatory mediators expression,10–14 the modu-
lation of inflammatory cell functions,15–18 and the in vitro 
regulation of osteoclasts.19 20 We have recently described 
in vivo that celastrol has significant anti-inflammatory 
and antiproliferative properties, with a decrease in the 
overall synovial inflammatory cellularity, and most impor-
tantly in the number of sublining CD68+ macrophages, 
a biomarker of drug efficacy in RA.9 21 In this study, we 
have hypothesised that celastrol is able to control inflam-
mation, and the focal and systemic bone resorption that 
occurs in arthritis.
Our aim was to evaluate the ability of celastrol to prevent 
disturbances on bone structure and strength induced by 
inflammation in the adjuvant-induced arthritis (AIA) rat 
model.
MateRIals and MetHOds
animals
Eight-week-old female Wistar AIA rats weighing 230-250 g 
were purchased from Charles River Laboratories Inter-
national (Wilmington, USA). Charles River Laborato-
ries performed optimised induction of adjuvant disease, 
using Freund’s complete supplemented with myco-
bacterium and injected in the right footpad (solution: 
40 mg of mycobacterium/1 mL of paraffin oil; 0.1 mL of 
the solution per animal). AIA rats were maintained in 
specific pathogen-free facilities, randomly housed per 
groups under standard laboratory conditions (at 20°C–
22°C under 10-hour light/14-hour dark), and given free 
access to food (RM3, SDS Diets, Witham, UK) and water 
(Ultrapure). In addition, to minimise animal discomfort 
paper shavings were used as bedding material in Double 
Decker GR1800 cages (Tecniplast, Kettering, UK) with 
five animals per cage. In accordance with Directive 
2010/63/EU, all animal procedures were approved by 
the institutional animal welfare body (Órgão Responsável 
pelo Bem-estar Animal, ORBEA-iMM) and licensed 
by the Portuguese competent authority (Direcção 
Geral de Alimentação e Veterinária, licence number: 
0421/000/000/2016). Humane end-points were estab-
lished and animals were sacrificed when presenting the 
maximum inflammatory score (0–3)22 in more than two 
paws or when presenting more than 20% of body weight 
loss.
Celastrol treatment
The dose of celastrol (1 µg/g/day) used in this study was 
based on that used in our previous studies9 21 and in other 
studies.23 Also, we have already reported that this dose is 
effective in suppressing synovial inflammation in the AIA 
rat model, with no evidence of drug-induced toxicity.21 
Celastrol (Sigma, Sintra, Portugal) stock solution of 
100 mg/mL in dimethyl sulfoxide (DMSO) was dissolved 
in normal saline solution and injected intraperitoneally 
in the early treatment group of AIA rats since the fourth 
day of disease induction (n=15) and in the late treatment 
group since the 11th day of disease induction (n=15), and 
was maintained until day 22. Studies using the acute AIA 
model are generally completed at this time point due to 
a plateau effect of inflammatory manifestations. A group 
of healthy non-arthritic and arthritic untreated female 
age-matched Wistar rats sacrificed on day 22 after disease 
induction (chronic clinical stage) were used as controls in 
all experiments. The sample size in each group was calcu-
lated using free sample size calculating G*Power V.3.1.9.2 
software (type of power analysis: a priori; alpha (α) error 
probability: 0.05; power (1-beta (β) error probability): 
0.95; effect size d: 1.526112; actual power: 0.9576654). At 
the preclinical AIA progression stage, evidence of inflam-
mation or bone erosions is still lacking in the contralat-
eral hind paw and fore paws. Hind paw swelling, inflam-
mation and joint erosions steadily progress during acute 
clinical stage and reach a plateau in the chronic stage.24 
Rats were sacrificed by CO2 narcosis, and blood, femurs, 
tibiae and paw samples were collected.
Immunohistochemical staining of cathepsin K and 
osteocalcin positive cells in hind paws
Left hind paw samples, from the ankle joint, collected 
at the time of sacrifice were fixed immediately in 10% 
neutral buffered formalin solution and then decalcified 
in 10% formic acid. Samples were next dehydrated and 
embedded in paraffin, serially sectioned at a thickness of 
5 µm using a microtome, and mounted on microscope 
slides. Osteoclasts and osteoblasts immunolocalisation 
in subchondral bone tissue at the tibia/talus region 
was performed by staining with cathepsin K (osteoclast 
marker; mature osteoclast enzyme; Biorbyt, Cambridge, 
UK) and osteocalcin (osteoblast marker; indicator of 
osteoblastic activity; Abcam, Cambridge, UK) primary 
antibodies followed by EnVision+ (Dako, Glostrup, 
Denmark). Colour was developed in solution containing 
diaminobenzidine-tetrahydrochloride (Sigma, Sintra, 
Portugal), 0.5% H2O2 in phosphate-buffered saline 
buffer (pH 7.6). Slides were counterstained with haema-
toxylin and mounted. Immunohistochemical evaluation 
of rat joints was performed in a blinded fashion using 
a semiquantitative score of 0–3 (0: 0%–25% staining; 1: 
25%–50% staining; 2: 50%–75% staining; 3: more than 
75% staining) of the positively stained cells per total 
cellular count in the tissue section.9 21 25 Slides were 
analysed using a Leica DM2500 microscope (Leica 
Microsystems, Wetzlar, Germany).
serum biochemical measurement of bone and cartilage 
turnover markers
Bone and cartilage turnover was analysed by quantifying 
the levels of TRACP-5b (tartrate-resistant acid phos-
phatase 5b), P1NP (procollagen type 1 amino-terminal 
propeptide) and CTX-II (C terminal crosslinked telopep-
tide of type II collagen) in rat serum using ELISA (Immu-
nodiagnostic Systems, Boldon, UK). All the commercial 
assays were performed according to the manufacturers’ 
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instructions, and standard curves were generated using 
supplied reference concentrations. Samples were meas-
ured using a plate reader Infinite M200 (Tecan, Manne-
dorf, Switzerland).
Micro-Ct analysis
Structural properties of the trabecular and cortical tibiae 
were determined with a high-resolution micro-CT system 
(SkyScan 1272, Bruker micro-CT, Kontich, Belgium). 
Moist bones were wrapped in parafilm and covered with 
dental wax to prevent drying and movement during the 
scanning. X-ray tube voltage was set to 50 kV and the 
beam was filtered with 0.5 mm aluminium filter. Sample 
position and camera settings were tuned to provide 
3.0 µm isotropic pixel size and projection images were 
collected every 0.2°. Density calibration was performed 
against hydroxyapatite phantoms with densities of 
250 mg/cm3 and 750 mg/cm3. Image reconstruction was 
done with NRecon software (V.1.6.9.8; Bruker micro-CT) 
and appropriate corrections were applied to reduce 
beam hardening and ring artefacts. Trabecular bone 
was manually segmented from cortical bone, and trabec-
ular bone parameters were analysed over 1400 slices, 
starting 200 slices distal from growth plate. Cortical bone 
parameters were analysed over 300 slices, starting 1800 
slices distal from growth plate. Analyses were performed 
in agreement with guidelines for assessment of bone 
microstructure in rodents using micro-CT.26 Trabec-
ular bone morphology was analysed by applying global 
threshold and despeckling to provide binary image for 
three-dimensional (3D) analyses. Cortical bone region of 
interest (ROI) was refined with ROI-shrink wrap opera-
tion, which also provided cortical bone shape for two-di-
mensional morphological analysis. This was followed 
by segmentation of blood vessels using adaptive thresh-
olding. Blood vessels (porosity) were analysed using 3D 
morphological analyses.
nanoindentation measurements
Nanoindentation was performed using a CSM-Nano 
Hardness Tester System (Indentation V.3.83; CSM Instru-
ments SA, Switzerland) equipped with a Berkovich-based 
pyramid diamond indenter. After micro-CT, 0.5 mm of 
top tibia was cut and proximal part was embedded to 
low viscosity epoxy resin (EpoThin, Buehler, Knorring 
Oy Ab, Helsinki, Finland). Slow-speed diamond saw was 
used to remove 10% of bone length. The sample surface 
was polished using silicon carbide sandpaper with a 
decreasing grid size (800, 1200, 2400 and 4800) and 
finished with cloth containing 0.05 µm γ-alumina parti-
cles. Indentation protocol was adopted from previous 
work,27 and an average of eight indentations were done 
on both cortical and trabecular bone with quasistatic (so 
called ‘advanced’) loading protocol. All indentations 
were performed under an optical microscope to achieve 
the precise location of indentations at the centre of the 
targeted area in the tissue.28 In the advanced protocol, a 
trapezoidal loading waveform was applied with a loading/
unloading rate of 20 mN/min, and with an intermediate 
load-hold-phase lasting 30 s hold at a maximum load 
of 10 mN. The hardness (HIT), indentation modulus 
(EIT), indentation creep (CIT) and elastic part of inden-
tation work (ηIT) were measured by advanced protocol 
using the Oliver and Pharr29 method. Histological 
images of rat tibiae from diaphyseal cortical region were 
acquired during the nanoindentation technique, using 
a CSM Instruments microscope equipped with a colour 
camera. A histological score was applied to evaluate the 
lamellar structures of bone tissue. This evaluation was 
performed in a blind fashion using a semiquantitative 
score for the analysis of the lamellar bone structure (1: 
predominantly parallel-lamellae; 2: concentric and paral-
lel-lamellae in the same proportion; 3: predominantly 
concentric lamella). The ratio of osteocyte lacuna area/
total tissue area was also evaluated at ×200 magnification 
to analyse the percentage of total tissue area occupied by 
osteocyte lacunae. The method of acquisition and anal-
ysis used was the same applied for the evaluation of bone 
volume/tissue volume in histomorphometry technique.30 
All variables were expressed and calculated according to 
the recommendations of the American Society for Bone 
and Mineral Research,31 using a morphometric program 
(ImageJ 1.46R with plugin BoneJ).
FtIR quantification
Samples used for nanoindentation were also used for 
Fourier transform infrared spectroscopy (FTIR). Chem-
ical composition was measured from bone surfaces 
separately with the HYPERION 3000 FTIR microscope 
(Bruker Optics, Billerica, Massachusetts, USA) using 
attenuated total reflection (ATR) objective. The ATR 
crystal was compressed on the bone with a constant load, 
and spectral images were recorded with a focal plane 
array detector. Spatial and spectral resolutions were set 
to 1 µm and 2 cm−1, respectively. Each spectrum between 
840 and 3300 cm−1 was averaged 32 times, and two spectral 
maps (32×32 spectra) were collected from the trabecular 
and cortical bone separately. Data were analysed using 
a custom script in the Matlab environment (MathWorks, 
Natick, Massachusetts, USA). For each spectral map, areas 
under curves were calculated for amide I, phosphate and 
carbonate peaks by integrating spectra between 1595–
1720 cm−1, 900–1185 cm−1 and 850–895 cm−1, respectively. 
Blood vessels and other porous structures were removed 
by excluding spectra with maximum phosphate peak 
height less than 0.5 absorbance units. Average content as 
well as well-established parameters for bone composition 
(carbonate:amide I, mineral:matrix and carbonate:phos-
phate) were finally calculated from the threshold spectral 
maps.32
3-point bending biomechanical test
In order to investigate bone strength after celastrol treat-
ment, femurs were subjected to a 3-point bending test 
in a universal testing machine (Instron 3366, Instron, 
Norwood, USA) with a load-cell of 500 N. Femurs were 
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Figure 1 Celastrol reduces the number of bone-related cells in arthritic joints. (A) Representation of the immunohistochemical 
evaluation performed in left hind paw sections at the ankle joint by day 22 after celastrol treatment. Magnifications of 200× and 
400×. (B) Cathepsin K+ cells and osteocalcin positive cells were identified by immunohistochemistry of paw sections. 
Immunohistochemical analysis was performed using a semiquantitative score. Notice that celastrol treatment significantly 
reduced both types of cells. Samples were collected at the time of sacrifice. Data are expressed as median score with 
minimum and maximum interval. H, healthy; A, arthritic; E, celastrol early-treated; L, celastrol late-treated. Healthy, n=16; 
arthritic, n=10; celastrol early-treated, n=15; and celastrol late-treated, n=15.
placed horizontally, anterior side upwards, on a support 
with span length of 5 mm. The load was applied with a 
constant speed of 0.005 mm/s until a failure occurred. 
Stiffness was analysed by fitting first-degree polynomial 
function to the linear part of recorded load deformation 
data. The breaking point was defined when force reached 
a maximum value, and corresponding deformation and 
absorbed energy were analysed.
statistical analysis
The primary outcome of this study was to prevent the 
structural and mechanical damage of bone induced by 
inflammation, and the secondary outcome was to treat 
the structural and mechanical deterioration of bone in 
a chronic phase of arthritis development in the AIA rat 
model.
A number of characteristics, described above, were anal-
ysed using descriptive statistics (median with minimum 
and maximum interval for continuous variables) and 
box-plots.
Differences between the three independent groups 
(celastrol early and late treatment groups, and untreated 
arthritic rats) on these characteristics were assessed by 
non-parametric Mann-Whitney tests with Bonferroni 
correction. Thus, applying the Bonferroni correction, 
we divided the global significance level at 0.05 by the 
number of independent tests (3) to get the Bonferroni 
critical value, so a test would have to have p value <0.02 to 
be significant.
The Bonferroni correction is the most conservative 
correction. However, it is mainly useful when there are a 
fairly small number of multiple comparisons and we are 
looking for one or two that might be significant, as is here 
the case.
The Mann-Whitney test was also used to compare 
differences between the other two independent groups: 
healthy non-arthritic and untreated arthritic rats on the 
dependent variables. In these cases, p values <0.05 were 
considered to be significant.
All inferential statistical analyses were performed using 
the GraphPad Prism V.5.01 (GraphPad, La Jolla, USA).
Results
Celastrol effect on bone-related cells in arthritic joints
At treatment baseline, celastrol early-treated group had 
a mean inflammatory score of 1.5±0.7 and celastrol late-
treated group had a mean inflammatory score of 3.9±2.0. 
By the end of the treatment, both celastrol early-treated 
(0.7±0.9) and late-treated (1.5±0.2) groups reduced the 
inflammatory score compared with arthritic animals 
(8.0±2.0), with no differences in body weight.21
Arthritic rats showed an increase in the number of 
osteoclasts (cathepsin K+ cells) compared with healthy 
controls (figure 1). Importantly, celastrol administra-
tion significantly lowered the number of osteoclasts in 
comparison to arthritic rats. Arthritic rats also showed 
an increase in the number of osteoblasts (osteocalcin 
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Figure 2 Celastrol diminishes bone and cartilage resorption 
markers. (A) TRACP-5b, (B) P1NP and (C) CTX-II levels were 
quantified in rat serum samples collected at the time of 
sacrifice. Celastrol is able to significantly reduce the levels of 
TRACP-5b, P1NP and CTX-II in comparison with untreated 
arthritic rats. Data are expressed as median with minimum 
and maximum interval. H, healthy; A, arthritic; E, celastrol 
early-treated; L, celastrol late-treated. Healthy, n=13; 
arthritic, n=18; celastrol early-treated, n=15; and celastrol 
late-treated, n=15. CTX-II, C terminal crosslinked telopeptide 
of type II collagen; P1NP, procollagen type 1 amino-terminal 
propeptide; TRACP-5b, tartrate-resistant acid phosphatase 
5b.
positive cells lining bone surfaces) compared with 
healthy controls (figure 1). Notably, celastrol administra-
tion significantly reduced the number of these cells in 
comparison to arthritic animals.
Celastrol effect on bone resorption and cartilage degradation
To further elucidate the protective effect of celastrol on 
inflammation-mediated joint damage, bone and carti-
lage degradation markers were quantified. We measured 
serum levels of TRACP-5b as a marker of bone resorp-
tion, P1NP as a marker of bone formation and CTX-II as 
a maker of cartilage degradation. In the arthritic group, 
there was no significant increase in TRACP-5b levels 
at the end of the study period (figure 2A). TRACP-5b 
increases immediately after disease onset, and then 
gradually decreases throughout arthritis progression 
(online supplementary figure S1), as previously described 
by Stolina et al.33 34 Importantly, both in celastrol early-
treated and late-treated rats, there was a significant reduc-
tion in TRACP-5b levels compared with arthritic rats, 
suggesting a decrease in bone resorption. This reduction 
was also noticed in both treatment groups at an earlier 
time point (p=0.0014 in celastrol early-treated vs arthritic 
rats at baseline, day 4; and p<0.0001 in celastrol late-
treated vs arthritic rats at baseline, day 11; online supple-
mentary figure S1). In arthritic rats, there was an increase 
in serum P1NP (figure 2B) as a consequence of the high 
bone turnover, and in both treatment groups there was 
a significant drop in these levels compared with arthritic 
group. Finally, arthritic rats also revealed an increase in 
CTX-II levels due to cartilage degradation (figure 2C). 
Celastrol treatment significantly decreased these levels 
revealing that it is also effective in protecting cartilage 
integrity. Of note, although a strong tendency towards a 
decrease in CTX-II was observed in celastrol late-treated 
rats, it did not reach statistical significance.
Celastrol effect on bone structure
The effect of celastrol on inflammation-induced systemic 
bone loss was assessed by micro-CT analysis of tibial bones 
(figure 3). Representative reconstructions of micro-CT 
analysis of rat tibiae are shown in figure 3A. Arthritis 
progression led to significant reductions in trabecular 
bone mass and in trabecular bone volume fraction and 
number, and an increase in trabecular separation and 
porosity, compared with healthy controls (figure 3B). 
Also, the structural integrity declined with arthritis, as 
trabeculae had fewer connections and had rather rod-like 
appearance, indicated by increased structure model 
index. An 18-day course of therapy with celastrol, starting 
4 days after disease induction, preserved bone mass and 
integrity, with a significant increase in trabecular bone 
volume fraction (+16.6%) and number (+20.3%), as 
well as with a significant decrease in trabecular separa-
tion (−12.9%) and porosity (−4.5%), in comparison to 
arthritic rats. Celastrol treatment also preserved struc-
tural integrity, as trabeculae have more connections and 
have less rod-like appearance.
A similar pattern was observed in cortical bone 
(figure 3C). Arthritis decreased cortical bone area 
(−10.8%, p<0.0001) and thickness (−11%, p<0.0001) 
compared with healthy controls. Although overall 
cortical porosity was similar between arthritic and healthy 
controls, blood vessel channels were wider in arthritic 
bones. Both treatment approaches affected cortical bone 
by inhibiting bone resorption as shown by significantly 
smaller endosteal volume (−14.5% in early-treated and 
−20.1% in late-treated rats vs arthritic animals). Also both 
groups have significantly decreased cortical porosity 
(−18.2% in early-treated and −30.1% in late-treated rats) 
due to a decrease in the number (−17.1% in early-treated 
and −29.7% in late-treated animals) and thickness (−3.1% 
in early-treated and −4.8% in late-treated rats) of blood 
vessel channels, and thus significantly increasing their 
separation (+7.9% in early-treated and +14.6% in late-
treated groups) compared with arthritic rats.
Celastrol effect on bone matrix quality
Nanoindentation was performed in order to assess the 
quality at tissue matrix level (figure 4). Nanomechanical 
tests revealed that arthritic rats had a decrease in the 
hardness of cortical and trabecular bone in comparison 
with healthy controls (figure 4A). In contrast, rats treated 
with celastrol showed an increase in cortical bone hard-
ness; however, the same was not observed in trabecular 
bone. In addition, topographic images gathered during 
nanoindentation allowed the characterisation of bone 
histological features (figure 4B). Concentric lamellae 
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Figure 3 Celastrol preserves bone microarchitecture in arthritis. Inflammation-induced bone loss and bone microarchitecture 
degradation and the protective effect of celastrol are illustrated in representative micro-CT reconstructions (A). Trabecular 
(B) and cortical (C) bone indices were quantified from micro-CT reconstructions. Notice that tibiae from the celastrol early-
treated group have improved trabecular and cortical parameters compared with arthritic rats. Tibiae were collected at the time 
of sacrifice. Data are expressed as median with minimum and maximum interval. BV/TV, bone volume per tissue volume; H, 
healthy; A, arthritic; E, celastrol early-treated; L, celastrol late-treated. Healthy, n=30; arthritic, n=30; celastrol early-treated, 
n=15; and celastrol late-treated n=15.
were identified in secondary osteons and were more 
frequently observed in arthritic animals than in healthy 
controls and celastrol early-treated rats (figure 4A). On 
the contrary, healthy animals and celastrol early-treated 
animals presented more parallel-lamellae structures. 
Additionally, arthritic animals showed an increased area 
occupied by osteocyte lacunae in the total tissue when 
compared with healthy animals and both celastrol early-
treated and late-treated animals.
Celastrol effect on bone mineral content
FTIR was performed to assess the composition of cortical 
and trabecular bone. As shown in figure 5, results 
demonstrated a decreased mineral and collagen content 
in trabecular arthritic bone compared with healthy 
controls (figure 5A,B). Mineral content of trabecular 
bone was increased in celastrol late-treated group in 
comparison with arthritic animals (figure 5A). However, 
the major impact of celastrol was found in cortical bone 
with increased mineral content in early-treated and 
late-treated groups compared with arthritic animals 
(figure 5C). Results also demonstrated a significantly 
increased carbonate content in early celastrol-treated and 
late celastrol-treated groups in comparison with the 
arthritic group (figure 5D).
Celastrol effect on bone mechanical properties
Bone strength of rat femurs was evaluated using the 
3-point bending test (figure 6). There was a reduction 
in the maximal load that arthritic femurs were able to 
resist before breaking as compared with healthy controls 
(−13.6%, figure 6A), as well as in the capability to absorb 
energy (−29.6%, figure 6C). Early administration of 
celastrol improved bone strength and maximal load was 
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Figure 4 Bone mechanical properties assessed by nanoindentation in rat tibiae on day 22 post disease induction. (A) Results 
showed decreased cortical and trabecular hardness in the arthritic group when compared with healthy rats. Of notice, rats 
treated with celastrol showed increased hardness in cortical bone in comparison with untreated arthritic rats. (B) Illustrative 
topographic images of the histological features observed in the indentation tissue area. Concentric lamellae are identified in 
secondary osteons, characteristic of arthritic animals. On the contrary, parallel-lamellae are identified in healthy and celastrol 
early-treated groups. Magnification 20×. Tibiae were collected at the time of sacrifice. Data are expressed as median with 
minimum and maximum interval. HViT, Vickers hardness; Os.L/TV, osteocyte lacunae per tissue volume; H, healthy; A, arthritic; 
E, celastrol early-treated; L, celastrol late-treated. Healthy, n=28; arthritic, n=21; celastrol early-treated, n=14; and celastrol late-
treated, n=14.
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Figure 5 FTIR measurements from cortical and trabecular bone of rat tibia on day 22 post disease induction. FTIR 
measurements revealed that arthritic rats had mineral and collagen loss in trabecular bone (A and B). Celastrol-treated groups 
demonstrated increased mineral content of cortical and trabecular bone (A and C), as well as carbonate cortical content (D). 
Tibiae were collected at the time of sacrifice. Data are expressed as median with minimum and maximum interval. H, healthy; 
A, arthritic; E, celastrol early-treated; L, celastrol late-treated. Healthy, n=28; arthritic, n=21; celastrol early-treated, n=14; and 
celastrol late-treated, n=14. FTIR, Fourier transform infrared spectroscopy.
Figure 6 Celastrol effect on arthritic bone mechanical properties. Maximal load (A), maximal deformation (B), total absorbed 
energy (C), yield displacement (D), yield load (E), elastic energy (F) and stiffness (G) parameters were obtained by 3-point 
bending. Celastrol early-treated rats have higher levels of yield point displacement and maximum load compared with 
untreated arthritic rats. Femurs were collected after 22 days of disease induction. Data are expressed as median with minimum 
and maximum interval. H, healthy; A, arthritic; E, celastrol early-treated; L, celastrol late-treated. Healthy, n=13; arthritic, n=10; 
celastrol early-treated, n=15; and celastrol late-treated, n=15.
increased by 9.4%, when compared with arthritic group. 
Late celastrol administration was insufficient to correct 
bone damage, and these animals showed decreased 
maximal deformation and capability to absorb energy, 
which were significantly reduced by −14.7% (figure 6B) 
and −18.8% (figure 6C), respectively. Additionally, arthritic 
rats had a reduction in the yield displacement compared 
with healthy controls (−28,3%, figure 6D). In contrast, 
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in celastrol early-treated rats, there was an increase in 
the elastic properties of bone with an augmented yield 
displacement compared with arthritic rats (+20.7%), 
meaning that a higher elastic deformation of the femur 
occurred before the appearance of the first microfrac-
tures. In addition, mechanical results revealed that there 
was a significant reduction in the load (figure 6E) and 
elastic energy at yield point (figure 6F) in arthritic rats 
compared with healthy controls, only partially corrected 
in arthritic rats under celastrol treatment since the early 
phase of the disease (+7.4% and +34.8% than arthritic 
rats, respectively). Celastrol early-treated rats also showed 
a significant reduction in bone stiffness (figure 6G) in 
comparison to arthritic rats and celastrol late-treated rats 
(−7.5% and −17.8%, respectively). However, no differ-
ence was observed between healthy controls and arthritic 
rats in this mechanical parameter.
dIsCussIOn
In this study, the AIA rat model was used to assess the 
bone protective properties of celastrol in vivo, using 
novel techniques to accurately evaluate bone microar-
chitecture, mechanics and chemical composition. Here 
we demonstrated for the first time an inhibition of joint 
destruction and a reduction of systemic bone degrada-
tion after celastrol treatment, translated by the preserva-
tion of its structure. This might have implications for RA 
treatment, as bone disturbances constitute a major issue 
in this disease.35
We have previously shown that celastrol reduces the 
number of synovial macrophages,21 which are critical in 
osteoclast differentiation.1 Most importantly, we had also 
shown that celastrol inhibits NF-kB activation in vitro,9 a 
crucial step in osteoclast formation and function, upstream 
activated by the engagement of the receptor activator of 
NF-kB ligand (RANKL) with RANK. Recently, in vitro 
findings showed that celastrol inhibits the recruitment of 
TGFβ-activated kinase (TAK)1, an upstream receptor-as-
sociated factor of IκB kinase, to RANK and TNF recep-
tors,36 inhibiting both RANKL-induced NF-kB activation 
and the osteoblast-related extracellular signal-regulated 
kinase (ERK) signalling.19 Work from the Moudgil Labo-
ratory has shown, in vitro, that celastrol reduces other 
osteoclastic mediators besides RANKL, suggesting a shift 
in bone remodelling in favour of an antiosteoclastic 
activity.23 Finally, it has been reported in bone metas-
tasis and ovariectomy-induced bone loss models that 
celastrol reduces osteoclast numbers and bone loss and 
preserves its trabecular architecture, together with an 
inhibitory effect on osteoblasts’ viability and function.19 37 
By the end of the treatment, AIA rats treated with celas-
trol had less inflammatory signs and ankle swelling than 
untreated animals, with no association with drug-induced 
weight loss nor with increased risk of infections. Also, 
celastrol administration was not associated with hepato-
toxicity, nephrotoxicity nor with lung or spleen distur-
bances.21 In line with this previous evidence, we have 
shown in this study that celastrol significantly decreases 
the number of joint tissue osteoclasts and osteoblasts. 
Importantly, the gold standard treatment for RA, meth-
otrexate, also acts in a similar way, slowing down artic-
ular damage by inhibiting osteoclastogenesis,38 which is 
coupled to a reduction in osteoblasts proliferation.39 The 
immune-regulatory effects of methotrexate have some 
overlapping features with celastrol, such as modulation 
of cytokine secretion40 41 and NF-kB activity inhibition,42 
but also includes reactive oxygen species (ROS) genera-
tion leading to cell cycle arrest, apoptosis and changes in 
monocyte-endothelial adhesion,43 inhibition of synovial 
fibroblasts proliferation and neutrophil chemotaxis,44 
DNA hypomethylation in blood cells45 and defective Treg 
cell function reversion.46 Importantly, despite the lack of 
a head-to-head comparison analysis, data have recently 
suggested that an extract of TwHF, containing celastrol, 
is effective and safe in the treatment of RA and might 
have an efficacy comparable to the existing conventional 
synthetic disease-modifying antirheumatic drugs, such as 
methotrexate.47
The reduction in osteoclast and osteoblast numbers is 
consistent with the significant reduction in serum levels 
of TRACP-5b and P1NP observed in arthritic rats treated 
with celastrol, suggesting a reduction in the accelerated 
bone turnover induced by arthritis.
We have also quantified serum CTX-II. This is a major 
component of articular cartilage48 with a good correla-
tion between serum levels and the severity of cartilage 
damage.49 50 Celastrol treatment significantly reduced 
serum CTX-II concentration, suggesting a chondropro-
tective effect. This protective effect on cartilage could 
be explained by the inhibition of heat shock protein 90β 
and of NF-kB activation,51 combined with the control of 
inflammation.
Trabecular bone microarchitecture is an important 
feature of bone quality.52 Notably, celastrol treatment 
significantly improved arthritis-induced trabecular bone 
degradation and mitigated bone loss. Consistent with 
this, our results showed that celastrol administration 
prevented the loss of bone mechanical compliance of 
femurs in arthritic rats by preserving maximum load 
and yield displacement. In addition, celastrol-treated 
arthritic animals also showed positive effects on cortical 
bone morphology, which is a major factor defining the 
mechanical properties of bone. Furthermore, celas-
trol-treated animals had increased bone cortical hard-
ness. This is probably explained by the observation in 
cortical bone of a higher frequency of parallel-lamellae 
structures, which are 10% harder than concentric 
lamellae.53 In fact, concentric lamellae organised in 
secondary osteons microstructures have been associated 
with high bone remodelling and decreased hardness 
in nanoindentation.30 53 54 Other explanation for the 
differences related with hardness is that arthritic animals 
showed an increased number of osteocyte lacunae and 
of the area occupied by these lacunae in the total tissue. 
Celastrol early-treated group was able to preserve bone 
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matrix, with maintenance of the lacunae area per tissue 
volume. Osteocytes are responsible for the maintenance 
of bone homeostasis, and their irregular morphology has 
been associated with altered ability of the bone to reply 
to mechanical stimuli leading to significant changes in 
the structure and mineral density.55 In addition, these 
changes in osteocyte lacunae morphology might be 
related to osteocyte apoptosis, which could promote 
bone necrosis, leading to mineral loss and decreased 
hardness with consequent mechanical weakness.55
Finally, FTIR measurements demonstrated that inflam-
mation induces bone mineral and collagen loss in trabec-
ular bone. In contrast, celastrol was able to preserve and 
even increase mineral content of bone tissue matrix, 
especially in the late-treated group. FTIR results were also 
consistent with a decreased bone turnover rate, revealed 
by significantly increased levels of carbonate content in 
celastrol-treated groups.
The bone protective effect of celastrol can be mainly 
attributed to its anti-inflammatory properties, such as 
inhibition of proinflammatory cytokines, which are 
upstream of RANKL in the osteoclastogenic pathway and 
suppression of metalloproteinases (MMPs) via NF-kB 
inhibition. Celastrol bone-preserving effect has also been 
demonstrated in cancer models, which is supportive of 
these data. Cancer and arthritis share common inflam-
matory pathways such as the NF-kB pathway, which is a 
molecular target of this small molecule. In addition, in 
an experimental mice model of secondary osteoporosis, 
celastrol treatment ameliorated abnormal bone metabo-
lism also via NF-kB and MMPs inhibition.56
Despite celastrol efficacy there are still some differ-
ences between treated and healthy phenotypes; there-
fore, it is reasonable to speculate that the extent of bone 
protection could be even further improved by optimised 
doses of celastrol or by augmenting treatment duration, 
which is not possible when using the AIA model.
In conclusion, celastrol halted joint destruction and 
preserved structural and mechanical bone properties, 
and thus may serve as a useful therapeutic agent for the 
treatment of inflammation-induced bone damage.
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